Use of potassium canrenoate to suppress ouabain-induced ventricular arrhythmias in dogs.
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000139:chemically induced* / Q000188:drug therapy; D001794:Blood Pressure / Q000187:drug effects; D003864:Depression, Chemical; D004232:Diuretics / Q000494:pharmacology; D004285:Dogs; D004562:Electrocardiography; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects*; D006914:Hydroxysteroids / Q000008:administration & dosage / Q000494:pharmacology; D007664:Ketosteroids / Q000008:administration & dosage / Q000494:pharmacology; D000451:Mineralocorticoid Receptor Antagonists; D010042:Ouabain / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D011245:Pregnadienes / Q000008:administration & dosage / Q000494:pharmacology*; D011422:Propionates / Q000008:administration & dosage / Q000494:pharmacology; D013610:Tachycardia / Q000139:chemically induced
D004232:Diuretics; D006914:Hydroxysteroids; D007664:Ketosteroids; D000451:Mineralocorticoid Receptor Antagonists; D011245:Pregnadienes; D011422:Propionates; D010042:Ouabain